Video
Dr. Vaishampayan highlights new options in second-line urothelial cancer
Author(s):
Video Player is loading.
Ulka Nitin Vaishampayan, MBBS, director, Phase I Program, Rogel Cancer Center, Michigan Medicine, professor of internal medicine, University of Michigan, discusses new options available for the second-line treatment of urothelial cancer, including the antibody-drug conjugates enfortumab vedotin (Padcev) and sacituzumab govitecan (Trodelvy).
Newsletter
Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.
Related Videos
TMT for bladder cancer: Balancing cost and quality of life
Anne Schuckman, MD, outlines current challenges in NMIBC care
Investigators compare trimodal therapy vs cystectomy in MIBC
Investigators assess ctDNA’s role in NMIBC
RX Review: Implementing mitomycin for LG-IR-NMIBC in clinical practice
RX Review: TURBT vs chemoablation for low-grade, intermediate-risk NMIBC
RX Review: A paradigm shift for low-grade, intermediate-risk NMIBC
RX Review: How mitomycin for intravesical solution works in treating LG-IR-NMIBC
RX Review: Redefining treatment for LG-IR-NMIBC
Vignesh Packiam, MD, on the MOA, dosing of detalimogene voraplasmid
Related Content
